Oligodendroglioma Therapeutics Pipeline Market H2 2014 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Oligodendroglioma – Pipeline Review, H2 2014” report to its store. The report provides an overview of the oligodendroglioma’s therapeutic pipeline.

Oligodendroglioma Therapeutics Pipeline Market

Oligodendroglioma Therapeutics Pipeline Market

The report “Oligodendroglioma – Pipeline Review, H2 2014″ provides comprehensive information on the therapeutic development for Oligodendroglioma. An oligodendroglioma is a rare type of brain tumour. Oligodendroglioma is most frequently occurring in young and middle-aged adults. Oligodendrogliomas represent approximately 5% of all gliomas. The exact cause of oligodendroglioma is not known. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/oligodendroglioma-pipeline-review-h2-2014-market-report.html .

The report also reviews key players involved in the therapeutic development for oligodendroglioma and special features on late-stage and discontinued projects. Companies discussed in this Oligodendroglioma – Pipeline Review, H2 2014 report include Cavion LLC, Celgene Corporation, Celldex Therapeutics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Orbus Therapeutics, Inc., Sanofi, Takeda Oncology, Tocagen Inc.

Seizures (fits) can be the first symptom of oligodendroglioma disease. Drugs profile discussed in this report include alisertib, bevacizumab, CC-122, Cell Therapy for Gliomas, Dendritic Cell Therapy for Oncology, DNX-2401, eflornithine hydrochloride, galunisertib, mibefradil dihydrochloride, panobinostat, plerixafor, rindopepimut, Stem Cell Therapy for Glioma, vocimagene amiretrorepvec, flucytosine ER. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=256174 . (This is a premium report priced at US$2000 for a single user License.)

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of content

List of Tables
Number of Products under Development for Oligodendroglioma, H2 2014 9
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Oligodendroglioma - Pipeline by Cavion LLC, H2 2014 17
Oligodendroglioma - Pipeline by Celgene Corporation, H2 2014 18
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H2 2014 19
Oligodendroglioma - Pipeline by Eli Lilly and Company, H2 2014 20
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 21
Oligodendroglioma - Pipeline by Novartis AG, H2 2014 22
Oligodendroglioma - Pipeline by Orbus Therapeutics, Inc., H2 2014 23
Oligodendroglioma - Pipeline by Sanofi, H2 2014 24
Oligodendroglioma - Pipeline by Takeda Oncology, H2 2014 25
Oligodendroglioma - Pipeline by Tocagen Inc., H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Oligodendroglioma Therapeutics - Recent Pipeline Updates, H2 2014 72
Oligodendroglioma - Dormant Projects, H2 2014 88

List of Figures
Number of Products under Development for Oligodendroglioma, H2 2014 9
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 14
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Top 10 Targets, H2 2014 29
Number of Products by Stage and Top 10 Targets, H2 2014 29
Number of Products by Top 10 Mechanism of Actions, H2 2014 31
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 31
Number of Products by Top 10 Routes of Administration, H2 2014 33
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 33
Number of Products by Top 10 Molecule Types, H2 2014 35
Number of Products by Stage and Top 10 Molecule Types, H2 2014 35

Explore more reports on Women's Health therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website